Kolexia
Santana Clémence Hématologie
Santana Clémence
Hématologie
Centre Léon-Bérard
Lyon, France
39 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Leucémie myéloïde Leucémie aigüe myéloïde Leucémies Syndromes myélodysplasiques Lymphomes Lymphome malin non hodgkinien Tumeurs hématologiques Lymphome T Carcinomes

Collaborateurs

Voir plus
Belhabri Amine
Belhabri Amine
Centre Léon-Bérard, Lyon, France
Michallet Anne-Sophie
Michallet Anne-Sophie
Centre Léon-Bérard, Lyon, France
Nicolas Virelizier Emmanuelle
Nicolas Virelizier Emmanuelle
Centre Léon-Bérard, Lyon, France
Rey Philippe
Rey Philippe
Centre Léon-Bérard, Lyon, France

Industries

Voir plus
Sanofi
3 collaboration(s)
Dernière en 2023
Abbvie
3 collaboration(s)
Dernière en 2023
Amgen
3 collaboration(s)
Dernière en 2023
Novartis
3 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome (SELECT MDS-1)
Essai Clinique (Syros Pharmaceuticals)   11 mars 2024
Real World Use of Azacitidine and Venetoclax in Acute Myeloid Leukemia in Frontline and Relapse/Refractory Settings: A Multicentric Study from French Auraml Group
65th ASH Annual Meeting Abstracts   02 novembre 2023
Efficacy and Safety of Luspatercept +/- Erythropoiesis-Stimulating Agent (ESA) in Patients with Myelodysplastic Syndromes with Ring Sideroblasts (MDS-RS): A French Multicenter Prospective Real-Life Registry
65th ASH Annual Meeting Abstracts   02 novembre 2023
TRANSCRIPT: Transplantation After Complete Response In Patients With T-cell Lymphoma
Essai Clinique (Hospices Civils de Lyon)   26 septembre 2023
POSTER: AML-454 Real-World Use of Azacitidine (AZA) and Venetoclax (VEN) in Acute Myeloid Leukemia (AML) in Frontline and Relapse/Refractory (R/R) Settings: Multicenter Study From French AURAML Group
Proceedings of the Society of Hematologic Oncology 2023 Annual Meeting   01 septembre 2023
AML-454 Real-World Use of Azacitidine (AZA) and Venetoclax (VEN) in Acute Myeloid Leukemia (AML) in Frontline and Relapse/Refractory (R/R) Settings: Multicenter Study From French AURAML Group
Proceedings of the Society of Hematologic Oncology 2023 Annual Meeting   01 septembre 2023
OCAPI: An Interventional Prospective Study to Test the Feasibility of an Individualized Physical Activity Program in Patients Over 65 Years of Age With Hematologic Malignancies: the OCAPI Project.
Essai Clinique (Centre Léon-Bérard)   29 août 2023
PASCA: Study of Complications Related to Treatments in Adults Aged 18 to 65 Years Old Responding to a First Treatment in Oncology or Onco-hematology and Participating in the PASCA (PArcours de Santé au Cours du CAncer) Post-treatment Program.
Essai Clinique (Centre Léon-Bérard)   29 août 2023
Clinical outcome of therapy-related acute myeloid leukemia patients. Real-life experience in a University Hospital and a Cancer Center in France.
Cancer medicine   07 août 2023
CCM : Connaitre & Combattre les Myelodysplasies - Besoin d'aide pour ...
Myelodysplasies.org   01 avril 2023